Lung Cancer and Leukemia Recap at ASCO 2021: Drs Ed Kim and Anthony Mato

Now Viewing

EP: 1.Lung Cancer and Leukemia Recap at ASCO 2021: Drs Ed Kim and Anthony Mato

EP: 2.Insights in Breast Cancer, GI Malignancies at ASCO 2021: Drs Milind Javle and Erika Hamilton

EP: 3.Updates in Genitourinary, Gynecologic Cancers From ASCO 2021: Drs Nick Vogelzang and Erin Crane

EP: 4.Latest in Myeloma, Prostate Cancer, and Lymphoma From ASCO 2021: Drs Neal Shore, Loretta Nastoupil, and Sandy Wong

Today-

We are reporting from the 2021 ASCO Annual Meeting!

We are highlighting some of the top news presented each day during the meeting—and soon we’ll speak with Dr. Ed Kim to discuss some new data in lung cancer, and Dr. Anthony Mato to recap some top findings in leukemia.

Welcome to OncLive News Network! I’m Gina Mauro.

In non–small cell lung cancer, updated findings from the phase 2 CodeBreaK100 trial showed that totorasib provided continued durable clinical benefit in patients with pretreated KRAS p.G12C–mutated disease.

Amivantamab combined with lazertinib elicited responses in more than one third of chemotherapy-naïve patients with EGFR-mutant non–small cell lung cancer who had progressed on osimertinib, according to data from a cohort of the CHRYSALIS trial.

Nivolumab and ipilimumab plus 2 cycles of platinum-based chemotherapy demonstrated a durable survival benefit vs chemotherapy alone in patients with advanced non–small cell lung cancer, as seen in the 2-year follow-up analysis of the phase 3 CheckMate 9LA trial.

In the phase 2 SPEARHEAD-1 trial, encouraging initial durability has been observed with afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

A single infusion of the CAR T-cell therapy brexucabtagene autoleucel demonstrated robust and durable responses in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia, as seen in the ZUMA-3 trial.

In acute lymphoblastic leukemia, phase 2 data demonstrated with the combination of ponatinib and blinatumomab represent a potentially promising chemotherapy-free, hematopoietic stem cell transplant —sparing treatment for patients with Philadelphia chromosome–positive disease.

Please be sure to check out more of our coverage from the 2021 ASCO Annual Meeting.

That’s all for today. Catch us tomorrow, where we will sit down with Dr Milind Javle to discuss the latest in gastrointestinal cancers, as well as Dr Erika Hamilton to speak about some top breast cancer studies.

Thank you for watching OncLive News Network: On Location, I’m Gina Mauro.